Roivant Sciences Ltd. officer Eric Venker filed a Form 144 notice on October 28, 2026, proposing the sale of 200,000 common shares on NASDAQ under a Rule 10b5-1 trading plan adopted on June 30, 2026.

Key Highlights

  • Proposed sale: 200,000 common shares of Roivant Sciences Ltd. with an aggregate market value of $7,317,764.00, according to the filing.
  • Approximate sale date: October 28, 2026, through broker Rockefeller Financial LLC, 45 Rockefeller Plaza, Floor 5, New York, NY 10111.
  • Shares outstanding: The filing lists 722,323,015 common shares outstanding at the time of notice.
  • Trading plan: The filing states the shares "will be sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 06/30/2026."
  • Acquisition sources: The shares to be sold were acquired through options exercises (grant date 04/20/2022) and RSU grants (grant dates 05/20/2020 and 05/20/2021), acquired between October 2023 and June 2025.
  • Recent prior sales: Venker sold common shares on three prior occasions in the past three months: 13,909 shares on 08/20/2026 for $512,407.56; 200,000 shares on 08/28/2026 for $7,147,087.91; 200,000 shares on 09/30/2026 for $7,323,556.00; and 200,000 shares on 10/20/2026 for $7,023,513.39.

Venker's Proposed October 2026 Sale Under 10b5-1 Plan

Eric Venker, identified in the filing as an officer of Roivant Sciences Ltd. (NASDAQ:ROIV), filed a Form 144 notice dated October 28, 2026, disclosing a proposed sale of 200,000 common shares. According to the filing, the aggregate market value of the shares to be sold is $7,317,764.00, and the transaction is to be executed through Rockefeller Financial LLC in New York. The filing lists 722,323,015 total common shares outstanding.

The filing attributes the shares proposed for sale to multiple acquisition events. These include options exercises from a grant dated April 20, 2022, resulting in 14,023 shares acquired on March 20, 2025, and 145,801 shares acquired on June 2, 2025. Additional shares came from RSU Grant 018305 (grant date May 20, 2020), with tranches of 8,847, 8,847, and 11,110 shares acquired in January, February, and March 2025, respectively. Shares from RSU Grant 018861 (grant date May 20, 2021) include tranches of 4,087, 3,913, and 3,372 shares acquired between October 2023 and March 2024.

The filing discloses that in the three months preceding this notice, Venker sold 613,909 common shares across four separate transactions, generating aggregate gross proceeds of $22,006,564.86. All sales are stated to be made under the Rule 10b5-1 trading plan adopted on June 30, 2026. The notice was signed by Carmen Zamores as a duly authorized representative of National Financial Services LLC, acting as attorney-in-fact for Eric Venker.

What Was Disclosed

A Form 144 notice was filed by Roivant Sciences Ltd. officer Eric Venker on October 28, 2026, proposing to sell 200,000 common shares valued at $7,317,764.00 through Rockefeller Financial LLC on NASDAQ, pursuant to a 10b5-1 plan adopted June 30, 2026.